Simple Summary Immunotherapy has revolutionized the therapeutic options for patients
living with non-small-cell lung cancer (NSCLC). Despite the unprecedented results achieved …

Simple Summary Immune checkpoint inhibitor (ICI)-based immunotherapy has dramatically
improved the survival of patients with advanced non-small cell lung cancer (NSCLC); …

Although previous studies suggest that cancer cachexia is a poor prognostic factor for
immune checkpoint inhibitor monotherapy, the impact of cancer cachexia on …

Objective The association between cancer-induced weight-loss (CIWL) and poor clinical
outcomes in patients treated with immunotherapy is scarcely understood. We evaluated the …

Non–small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancers. In recent
years, treatment with immune checkpoint inhibitors (ICIs) has gradually improved the …

Immunotherapy against cancer, through immune checkpoint inhibitors targeting the
programmed cell death‐1/programmed cell death‐ligand 1 axis, is particularly successful in …

Background The presence of cachexia negatively impacts the prognosis of patients with
cancer. However, the mechanisms behind the development of cachexia and its prognostic …

Cachexia is associated with decreased survival in cancer patients and has a prevalence of
up to 80%. The etiology of cachexia is poorly understood, and limited treatment options …

Background Immunotherapy has revolutionized cancer treatment. Recent studies have
suggested that the efficacy of immunotherapy can be further enhanced by the influence of …

Cancer immunotherapy including immune checkpoint inhibitors (ICI) has revolutionized non-
small cell lung cancer (NSCLC) therapy. Recently, the microbiota status “before” initiation of …